Based on the Phase 3 TRIUMPH calendar and Health Canadas typical lag behind FDA decisions, late 2027 is the earliest plausible window and mid-2028 is more conservative
83% of participants Achieved A1c less 7% Lost up to 11.3 kg (24.86lbs) Lower incidence of hypoglycemia (lower blood glucose) with tirzepatide Side effects: Mild to moderate gastrointestinal events
Alternative approaches to consider If Brello does not feel like the right fit, or if you want to explore all options before committing, consider: Oral tirzepatide options that eliminate injection anxiety entirely Tirzepatide sublingual drops as a needle-free alternative Orally disintegrating tablets for convenient dosing Phentermine comparison if you are weighing older weight loss medications against GLP-1 options Retatrutide , a next-generation triple agonist still in clinical trials but showing promising results For researchers interested in the broader peptide landscape, understanding how tirzepatide compares to emerging compounds like survodutide , orforglipron , and CagriSema provides valuable perspective on where GLP-1 therapy is heading
A price tag of $300-$350 per month is still significant, but it may make GLP-1 therapy potentially attainable for some middle-income uninsured individuals
GLP-1 helps control appetite, balance blood sugar, reduce cravings, and support fat loss while protecting lean muscle
Some individuals may also notice a decrease in appetite, which is part of semaglutides mechanism to help with weight loss